Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arcoxia Needs Further Study In 1,000s Of Patients, Or Discontinuation – Cmte

Executive Summary

Merck's COX-2 inhibitor Arcoxia requires significant additional clinical safety and efficacy evaluation prior to approval, members of FDA's Arthritis Drugs Advisory Committee said in recommending against approval of the Vioxx follow-on for treatment of osteoarthritis

You may also be interested in...



FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance

FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency

FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance

FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency

Novartis Is Confident In Prexige’s Prospects Despite Arcoxia AC Debacle

Novartis is confident its COX-2 inhibitor Prexige does not raise the same safety concerns cited by an FDA advisory committee in recommending against approval of Merck's COX-2 agent Arcoxia

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel